Regulatory decisions pertaining to aprotinin may be putting patients at risk
2014
The antifibrinolytic agent aprotinin, a naturally occurring serine protease inhibitor, was removed from the worldwide market in October 2007.[1][1] Aprotinin and two other antifibrinolytic agents (the lysine analogues tranexamic acid and aminocaproic acid) had been used in cardiac surgery to
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
22
References
13
Citations
NaN
KQI